Short answer
ARTIVION, INC. (AORT) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $124M (up 9.2% year over year) with net income of −$8M.
Q3 2026 key financials · XBRL
- Revenue
- $124M
- +9.2% YoY · −1.6% QoQ
- Net income
- −$8M
- −221.9% YoY · +41.3% QoQ
- Operating margin
- 2.4%
- Gross margin
- 61.4%
- EPS (diluted)
- −$0.16
- −214.3% YoY · +42.9% QoQ
Source: XBRL data from the ARTIVION, INC. (AORT) Q3 2026 10-Q on SEC EDGAR. USD.
ARTIVION, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $123.8M, up 9% YoY from $113.4M
- Gross margin 61% vs 66% YoY, pressured by higher costs and unfavorable mix
- Best performer: Other revenue $4.6M, up 93%; worst: Surgical sealants $18.9M, flat YoY
- Cash $48.4M, operating cash flow $(4.7)M vs $20.3M YoY
- Endospan acquisition used $116.7M; $150.0M term loan raised; PerClot manufacturing expected to end by year-end 2026
Risk Factors
- Italian medical-device repayment exposure, approximately $2.3 million for 2019–2025, pending government assessment
- Endospan acquisition completed May 18, 2026, adding NEXUS manufacturing concentration in Herzliya, Israel amid regional conflict
- CryoValve SGPV reclassification risk, potential Class III designation could make continued processing commercially infeasible
- FDA and other regulatory review delays, reduced federal staffing could delay clinical trials and product approvals
- Variable-rate indebtedness, covenant breach could accelerate repayment and permit foreclosure on substantially all US assets
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARTIVION, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.